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Exposure of pubertal mouse Leydig cells for 24 h to increasing concentrations (l-100 ng/ml) of LH elicited a dose- 
dependent decrease in AVP receptor content. Maximal reduction (50%) was obtained at a dose of 10 ng/ml LH. A similar 
treatment applied to adult Leydig cells did not influence AVP receptor density. Treatment of adult Leydig cells for 24 
h by E, (5500 ng/ml) resulted in a dose-dependent increase in AVP receptor content. About 50% increase was achieved 
with 500 ng/ml E2. AVP receptor content in pubertal Leydig cells was not modified irrespective of the concentration 
of E, tested. These changes in AVP receptor number were well correlated with the response of Leydig cells to AVP (lo4 
M) in terms of testosterone production. 2 weeks bilateral cryptorchidism resulted in reduction of testicular weight, circu- 
lating testosterone l vels associated with a marked rise in Lcydig cell AVP receptor density with no change of affinity. 
Testosterone production by Leydig cells from cryptorchid testes in response to AVP (lo4 M) or hCG (100 ng/ml) stimula- 
tion was reduced compared to that of control Leydig cells. This study provides new arguments upporting the concept 
that AVP could be involved in local regulation of testicular steroidogenesis. 
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1. INTRODUCTION 
Previous in vitro studies have demonstrated that 
the neurohypophysial hormones, AVP and OT, or 
related peptides can directly affect rat and mouse 
Leydig cell steroidogenesis. In both species an early 
stimulatory effect on testosterone production oc- 
curred in short-term treatment, but disappeared 
when the treatment was extended [1,2]. In contrast, 
a marked reduction in gonadotropin-stimulated 
androgen production appeared following a pro- 
longed exposure of Leydig cells to the neuropep- 
tides [l-4]. It has been suggested that the 
stimulatory effect could result from an increase in 
cholesterol side chain cleavage activity [5] while the 
inhibitory effect was the consequence of decreased 
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LH/hCG binding capacity [6] and lesion of 17cu- 
hydroxylase/ 17,20-desmolase activities ]2,41. 
Altogether these observations allowed to postulate 
that locally produced AVP-like hormone within 
the testis [7-91 could act as a paracrine regulatory 
component of Leydig cell function. 
We previously reported [lo] that AVP modulates 
steroidogenesis in purified mouse Leydig cells via 
specific Vi subtype. These results are in accordance 
with those [11,12] showing that AVP activates 
phosphoinositide breakdown in rat Leydig cells. 
More recently [ 131, we have found that at puberty, 
the AVP receptor density in mouse Leydig cells was 
markedly reduced as compared to adult, suggesting 
a possible regulation of this receptor throughout 
development. 
The present report concerns in vitro regulation 
by LH or EZ of AVP receptor content in mouse 
Leydig cells at puberty and adulthood. The find- 
ings were correlated with AVP-mediated testoster- 
one stimulation in short-term incubation, used as 
an index of hormone action [2]. AVP receptor con- 
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tent was also determined in Leydig cells derived 
from bilaterally cryptorchid mouse testes. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Arg3-Vasopressin (AVP) was provided by Calbiochem (San 
Diego, CA), [‘HIAVP (spec. act. 67 Ci/mmol) by New England 
Nuclear (DuPont de Nemours, FRG) and human chorionic 
gonadotropin (hCG, 9OQO IU/mg) by Boehringer Mannheim 
(France). Ovine luteinizing hormone (NIH oLH Sl) was a gift 
from Dr Jutisz (Laboratoire des Hormones Polypeptidiques, 
Gif-sur-Yvette). Medium 199, L-glutamine, sodium bicarbonate 
and Hepes were obtained from Eurobio (France). Bovine serum 
albumin (BSA) and collagenase type I (144 U/mg) were from 
ICN Pharmaceuticals (Uppsala). Deoxyribonuclease I (DNase 
I), gentamycin sulphate and 17@-estradiol (Ez) were from Sigma 
(St. Louis, MO). 
2.2. Experimental cryptorchidism 
Bilateral cryptorchidism was performed on adult Swiss mice 
by sewing the epididymis on the abdominal wall under ether 
anesthesia s previously described [141. Sham-operated animals 
served as controls. After 2 weeks, animals were killed, and 
blood was collected for testosterone measurement. Testes were 
weighed and served either for measurement of Ez content or for 
Leydig cell preparation. 
2.3. Preparation and culture of Leydig cells 
Leydig cells were prepared from testes derived from pubertal 
(35-38 days old), adult (80-90 days old) or cryptorchid mice ac- 
cording to a procedure previously described [15]. The percen- 
tage of pure Leydig cell preparations, determined by staining for 
3-hydroxysteroid dehydrogenase activity was 8090% for all 
groups. Viability of Leydig cells assessed by trypan blue exclu- 
sion was roughly 90%. 
Leydig cell cultures were performed as described elsewhere 
[2]. Culture medium consisted of Medium 199 supplemented 
with 0.1% BSA, 7 ,umol/ml L-glutamine, 350 ag/ml NaHC03, 
1 mmol/ml Hepes, 50pg/ml gentamycin sulphate and 
4.5 mg/ml glucose. Hormones to be tested, LH or Ez, were add- 
ed at the concentrations required, as indicated in section 3. 
Cultures were carried out at 37°C under air/C02 (95 : 5, v/v) for 
24 h. After treatment he cells were washed and recovered for 
binding assays. When AVP-stimulated testosterone production 
was studied, Leydig cells were cultured for 24 h in the presence 
of AVP alone or in combination with LH or Ez. Leydig cells 
were then washed and reincubated for a subsequent 3 h period 
in hormone-free medium prior to testosterone measurement. 
Responsiveness of Leydig cells to hCG was studied in the 
presence of a maximal dose (100 ng/ml) of hCG as previously 
reported [2]. 
2.4. A VP binding assays 
AVP binding assays were performed as described in [lo]. 
Leydig cells cultured for 24 h in the presence or absence of EZ 
or LH, or freshly prepared from cryptorchid and control testes, 
were used for AVP binding assays. Briefly, about lo6 Leydig 
cells/tube were incubated in the presence of [‘HIAVP at 4°C for 
90 min. Non-specific binding was determined by addition of an 
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excess of unlabeled AVP. Bound and free ligands were 
separated by cell filtration through Whatman GF/C filters. 
Radioactivity retained was counted in scintillation fluid (Ready 
Protein, Beckman). 
2.5. Steroid measurements 
Steroids in the plasma or testicular homogenates were ex- 
tracted with diethyl ether. Testosterone levels were determined 
in the extracts or directly in culture media by a specific radioim- 
munoassay as previously described [16]. Ez was measured in 
testicular extracts by ‘251-labeled estradiol radioimmunoassay 
kit (Baxter, FRG). 
2.6. Statistical analysis 
Student’s t-test or ANOVA and Duncan’s new multiple range 
test were used for statistical analysis of the data. 
3. RESULTS 
LH treatment of pubertal Leydig cells for 24 h 
reduced AVP receptor number (fig. 1, right). This 
decrease was dose-dependent and maximal reduc- 
tion (about 50%) was induced by a dose of 
10 ng/ml LH. A similar treatment applied to adult 
Leydig cells did not modify AVP receptor content 
whatever the concentration of LH tested. As 
shown in fig.1 (left), a 24-h EZ treatment of adult 
Leydig cells enhanced AVP receptor number in a 
dose-dependent fashion. Maximal increase (50%) 
was achieved with 500 ng/ml. Ez treatment of 
pubertal Leydig cells had no effect on AVP recep- 
tor content at any of the concentrations tested. 
As expected, the increase in AVP receptor 
number in adult Leydig cells after 24 h treatment 
with 500 ng/ml E2 is accompanied by a significant 
m._ Adult 
- Pubertal 
Ez(ng)mtl oLH (ng/ml) 
Fig. 1. Effects of 24 h treatment of Leydic cells with Ez or oLH 
on specific [‘H]AVP binding measured in the presence of 1 nM 
of the ligand. Receptor levels (fmol/106 cells) in untreated adult 
(6.02) and pubertal (2.39) Leydig cells were taken as 100%. 
Results are means of triplicate determination from a represen- 
tative of 3 experiments. 
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(PC 0.01) amplification of the stimulatory effect 
of AVP (10m6 M) on testosterone production 
(fig.2, left). Since the dose of LH (10 ng/ml) which 
maximally reduced AVP receptor number in 
pubertal Leydig cells was also able to increase tes- 
tosterone production (data not shown), a lower 
dose of LH which did not influence basal testoster- 
one production was used (fig.2, right). When 
0.1 ng/ml LH was concomitantly added with AVP 
(10e6 M) for 24 h, a significant (PcO.05) reduc- 
tion in the stimulatory effect of the neurohypo- 
physial hormone was observed (fig.2, right). Treat- 
ment for 24 h of pubertal and adult Leydig cells 
with E2 (500 ng/ml) and LH (0.1 ng/ml) respec- 
tively did not influence either basal (cells cultured 
without AVP) or AVP-stimulated testosterone pro- 
duction. 
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Fig.2. Effects of 24 h treatment of Leydig cells with Ez 
(500 ng/ml) or oLH (0.1 ng/ml) on AVP (lo-’ M) stimulated 
testosterone production. C: Leydig cells cultured in hormone- 
free medium. Results are means f SE of 3 different cultures. 
Columns with different letters are significantly different from 
each other (P<O.O5, Duncan’s new multiple range test). 
Experimental bilateral cryptorchidism resulted 2 
weeks later in a marked reduction (table 1) of 
testicular weight (P< 0.01) and plasma testoster- 
one levels (PcO.05). Ez content per testis was not 
changed between control and cryptorchid, but was 
2-3 times greater (P<O.Ol) in the cryptorchid 
when expressed per g testicular tissue. Binding 
studies (fig.3) indicate that bilateral cryptorchidism 
induced a striking rise in the number of AVP recep- 
tors in Leydig cells from cryptorchid testes. B,,, 
values (fmol/106 Leydig cells) rose from 15.6 in 
control to 49.7 in cryptorchid testes. No difference 
in the affinity (&) was observed between control 
(2.02 nM) and cryptorchid (2.19 nM) groups. This 
change in AVP receptor content was associated 
with a lower degree of testosterone stimulation by 
hCG (6- vs 46-fold stimulation, table 1). The 
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Fig.3. Scatchard plots of [3H]AVP binding in Leydig cells from 
control or cryptorchid adult mice. Cells were incubated in the 
presence of increasing concentrations of [‘H]AVP (0.2-6 nM). 
Results are the means of duplicate determinations from a 
representative of 2 experiments of each group. 
Table 1 
Effects of cryptorchidism on testicular weight, testicular E2 content, plasma testosterone and Leydig cell response to hCG 
Testicular Plasma Testicular EZ Testosterone production 
weight testosterone (ng/5 x 104 Leydig cells per 3 h) 
(mg) (ngjml) 
pg/testis pg/g tissue 
- hCG + hCG fold-stimulation 
Sham-operated 135 f 9.5 4.18 f 1.2 7.75 + 0.5 55.06 + 5.77 3.07 + 0.42 142.9 f 11.33’ 46 
(controls) (12) (8) (8) (8) (3) (3) 
Cryptorchids 50 f 4a 0.74 f 0.07b 6.81 + 0.6 133.25 f 15.48” 7.75 * 0.30 47.14 f 2.77’ 6 
(12) (8) (8) (8) (3) (3) 
Results are the means f SE of n determinations. aPcO.01 vs controls; b PcO.05 vs controls; ’ P< 0.001 vs respective unstimulated 
Leydig cells. Number of animals given in parentheses 
191 
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respone of Leydig cells from cryptorchid testes to 
AVP was also reduced. Testosterone production 
(means + SE) was 3.07 f 0.42 and 7.78 f 0.45 ng/ 
5 x 104 Leydig cells per 3 h in the absence, and 
7.75 & 0.30 and - 11.82 f 0.74 ng/5 x lo4 Leydig 
cells per 3 h in the presence of AVP in Leydig cells 
from control and cryptorchid testes, respectively. 
4. DISCUSSION 
The present data demonstrate for the first time 
that AVP receptors in Leydig cells are regulated by 
LH or Ez treatment. They indicate in addition, that 
these regulations differ markedly according to the 
maturational stages of the animals. The present 
results show that LH does not affect AVP receptor 
number in adult Leydig cells, whereas gonado- 
tropin is able to reduce these receptors at puberty. 
This latter result is strongly supported by the obser- 
vation that LH is also able to reduce the 
stimulatory effect of AVP on testosterone produc- 
tion by pubertal Leydig cells. Another argument in 
favor of negative control of AVP receptor by LH 
comes from recent data (Tahri-Joutei et al,, un- 
published) indicating that phospholipid breakdown 
elicited by AVP [ 11,121 is reduced by LH in puber- 
tal but not in adult Leydig cells. The possibility that 
such a heterologous down-regulation of AVP 
receptor by gonadotropin occurs in vivo during 
puberty may be considered, since the decreased 
number of AVP receptors at this stage [13] was 
coincident with the peaking of serum LH [17,18]. 
Whether this negative control of AVP receptor at 
puberty has physiological relevance remains to be 
clarified. 
The current study also shows that E2 is able to in- 
crease AVP receptor number associated with 
amplification of steroidogenic responsiveness of 
adult Leydig cells to AVP. A similar Ez-mediated 
up-regulation of AVP receptors has been reported 
in myometrium [ 191.’ The presence of estrogen 
receptor has been demonstrated in both mouse and 
rat Leydig cells [20]. In rat a lower EZ receptor con- 
tent in Leydig cells was found during sexual 
maturation as compared to adulthood [21]. If a 
similar pattern of E2 receptor change occurs in the 
mouse, this could explain the lack of E2 effect on 
AVP receptor in pubertal Leydig cells. However, 
the exact mechanism by which El induces increae 
of AVP binding in adult Leydig cell is presently un- 
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known. E2 is known to inhibit in vitro steroido- 
genesis in adult rat Leydig cells [22], but has no ef- 
fect in mouse Leydig cells [23]. The insensitivity of 
mouse Leydig cells to E2 may be explained by the 
rapid decrease in vitro of estrogen receptor levels 
[20]. Nonetheless, the present data clearly 
demonstrate a stimulatory effect of E2 on AVP 
receptor content in cultured mouse Leydig cells. In 
the rat the inhibitory effect of E2 on adult Leydig 
cell function is associated with synthesis of a 
specific protein of 27 kDa the nature and role of 
which are still unknown [22]. It is therefore attrac- 
tive to hypothesize that the protein identified by 
these authors could be related to AVP receptor. 
Cryptorchid animals have been used to in- 
vestigate the influence of seminiferous tubules on 
Leydig cell function. Our study shows that disrup- 
tion of spermatogenesis induced by cryptorchidism 
resulted in a reduction of testosterone biosynthesis 
accompanied by a striking increase in AVP recep- 
tor number in Leydig cells. Although, in the pres- 
ent study we have used the stimulatory effect of 
AVP on testosterone production as an index of 
hormone action [1,2], an inhibitory effect of 
neurohypophysial hormones on gonadotropin- 
stimulated androgen production has also been 
demonstrated in mouse and rat Leydig cells 
[l-4,6]. On the basis of our observations on the 
cryptorchid testes, it is tempting to speculate that 
the main physiological effect of neurohypophysial 
hormones in vivo is inhibitory. First the in vitro 
responsiveness of Leydig cells to hCG is markedly 
reduced in cryptorchid testes. Second, in spite of a 
3-fold increase of AVP receptor content in Leydig 
cells from cryptorchid testes, the AVP-stimulated 
testosterone production is not positively coupled to 
the AVP receptor increase. From our data it is 
presently difficult to ascertain whether the up- 
regulation of AVP receptors by EZ obsreved in 
vitro, occurs in the cryptorchid testis. The fact that 
EZ concentration increases when expressed per g 
testicular tissue in cryptorchid as compared to con- 
trol (present study, [24]) associated with the 
previous findings [25] that cryptorchid rat testes 
produced more E2 in vitro than controls under 
hCG stimulation, might support E2-mediated up- 
regulation of AVP receptor in cryptorchid testes. 
Accordingly, the possibility that E2 and AVP act in 
a synergistic manner to inhibit Leydig cell steroido- 
genesis cannot be excluded. Another explanation 
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for increased AVP receptor number could be that 
the seminiferous tubule produces a factor which 
controls AVP receptors in Leydig cells. Alteration 
of its production by damaged tubules could result 
in an increase in AVP receptors. We cannot ex- 
clude the possibility that up-regulation of AVP 
receptor results from a homologous down- 
regulation suppression, since it was demonstrated 
[26] that immunoreactive AVP content decreased 
in cryptorchid rat testes. Such a homologous 
down-regulation of AVP receptors has been 
reported for WRKl cells [27]. 
In conclusion, this study has demonstrated hor- 
monal regulation of Leydig cell AVP receptor den- 
sity accompanied by modification of the steroido- 
genie response to the neuropeptide. The changes in 
AVP receptor content during normal development 
[ 131 or after disruption of testicular function by ex- 
perimental cryptorchidism, provide new insight in- 
to the consideration that vasopressin could be one 
of the major paracrine factors regulating gonadal 
steroidogenesis. 
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